Retacrit, Epogen, or Procrit is to be approved contingent on the adverse effects in non-dialyzed CKD patients. However the data are
Retacrit is a biosimilar to Epogen/Procrit, two drugs used to treat anemia and reduce blood transfusions. It has the same indications, warnings, and labeling as Epogen/Procrit, but is not interchangeable with them.
Retacrit is biosimilar to the drugs Epogen and Procrit.
Aranesp, Epogen, Mircera, Procrit and Retacrit are erythropoiesis Stimulating Agents (ESA) which promote the Separated Rx vs MB policies.
Retacrit TM was approved by the US Food and Drug Administration in May 2024 as a biosimilar to US-licensed Epogen /Procrit, for all indications of the epoetin alfa reference product . Retacrit TM has an identical amino acid sequence and similar carbohydrate composition to Epogen /Procrit .
Compare Mircera vs Procrit head-to-head with other drugs for uses, ratings, cost, side effects and interactions. Other epoetin alfa brands include: Epogen, Retacrit:
Aranesp, Epogen, Mircera, Procrit and Retacrit are erythropoiesis Stimulating Agents (ESA) which promote the Separated Rx vs MB policies.
Procrit (epoetin alfa), Retacrit (epoetin alfa-epbx). Mircera Epogen/Procrit/Retacrit: 5 years of age and older. Aranesp: 18 years
Retacrit is a biosimilar to Epogen/Procrit, two drugs used to treat anemia and reduce blood transfusions. It has the same indications, warnings, and labeling as Epogen/Procrit, but is not interchangeable with them.
then vs than
accept vs expect
alright vs all right
its vs it's
there vs their
waist vs waste
your vs you're, you are